Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study
Journal of Oncology Pharmacy Practice · 2023-06 · 29 (4) · 794-801
DOI: 10.1177/10781552221079568 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 11.02.2022. Verfasst von Luis Gros und 11 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Oncología y Hematología Pediátricas, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Acute Kidney Injury, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BTG Specialty Pharmaceuticals.
Abstract (Originalsprache)
Introduction
High-dose methotrexate (HDMTX) is administered for the treatment of some cancers. HDMTX is usually safe but may crystallize in renal tubules causing acute kidney injury (AKI). Consequently, MTX elimination is delayed, resulting in a severe and life-threatening condition. No studies have been published about the impact of MTX toxicity in Spain. This study aims to estimate the incidence and management of MTX delayed elimination and toxicity.
Methods
A two-round Delphi study was performed to reach consensus between 10 medical experts on haemato-oncology and paediatric oncology with experience in the management of HDMTX treated patients from leading Spanish hospitals. An online questionnaire was developed based on national and international guidelines and previous evidence regarding HDMTX-related toxicity. Consensus was established at 80% agreement. Median and interquartile ranges were calculated, and incidence data were extrapolated to the Spanish general population.
Results
Out of 1.475 patients estimated to receive HDMTX treatment annually in Spain, 27.5% present MTX delayed elimination and 11.6% develop HDMTX-induced AKI (35.4% with severe systemic toxicities (>grade 3) and 18.8% develop chronic renal disease). Mortality is estimated in 4.2%. Immuno-enzymatic assay is used in most of the hospitals (90%) for MTX serum level monitoring. All experts use increased supportive care and high leucovorin as first-line treatment. Available treatments in experts’ hospitals in case toxicity persists are haemodialysis (90% of hospitals), glucarpidase (60%) and hemofiltration (50%). Most prevalent non-renal systemic toxicities are haematologic and mucositis (21–40% of patients). Patients with HDMTX-induced AKI require from intensive care (5% of patients), more than 3 sessions and 4 days of dialysis, and about 8.5 days of hospitalization (non-ICU patients) and 12 days in case of patients requiring ICU.
Conclusions
These results are the first evidence regarding HDMTX-induced AKI in Spain. Incidence and mortality results are in line with previous studies. Clinical management is based on preventive measures and the treatment depend on the availability in the hospital. The need for effective, safe and rapid treatment for the reduction of MTX toxic levels and the improvement of monitoring methods were noted by experts as urgent needs. Further observational studies to validate these results would be needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Oncología y Hematología Pediátricas, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Sección de Hematología y Hemoterapia, Hospital Universitario Infanta Sofía, Madrid, Spain.
- Departamento de Hematología y Hemoterapia, Hospital Universitario de Salamanca (HUS), Instituto Biomédico de Salamanca (IBSAL), Salamanca, Spain.
- Unidad de Hemato-Oncología Pediátrica, Complejo Hospitalario de Toledo, Toledo, Spain; Unidad de Hemato-Oncología Pediátrica, Hospital 12 de Octubre, Madrid. Instituto de Investigación i + 12, Hospital 12 de Octubre, Ma…
- Servicio de Hematología y Hemoterapia, MD Anderson, Madrid, Spain.
- Institut Català d'Oncologia, Hematology Department, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
ORCID-Profile: Alicia Roldán, Xavier Badia
Förderung
- BTG Specialty Pharmaceuticals
Zitieren
APA
Gros, L., Roldán, A., Cabero-Martínez, A., Domínguez-Pinilla, N., de la Fuente, A., González-Barca, E., Tasso, M., Torrent, M., Gallardo, E., Del Cerro, I., Giró-Perafita, A., & Badia, X. (2023). Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. Journal of Oncology Pharmacy Practice, 29(4), 794-801. https://doi.org/10.1177/10781552221079568
Vancouver
Gros L, Roldán A, Cabero-Martínez A, Domínguez-Pinilla N, de la Fuente A, González-Barca E, et al. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. Journal of Oncology Pharmacy Practice. 2023;29(4):794-801. doi:10.1177/10781552221079568
BibTeX
@article{Gros2023,
author = {Gros, Luis and Roldán, Alicia and Cabero-Martínez, Almudena and Domínguez-Pinilla, Nerea and de la Fuente, Adolfo and González-Barca, Eva and Tasso, María and Torrent, Montserrat and Gallardo, Eva and Del Cerro, Inés and Giró-Perafita, Ariadna and Badia, Xavier},
title = {Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study},
journal = {Journal of Oncology Pharmacy Practice},
year = {2023},
volume = {29},
number = {4},
pages = {794--801},
doi = {10.1177/10781552221079568}
}
EUVIMED